Abstract
Objective: To analyze the application value of Elouzumab in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI), so as to lay a foundation for the follow-up treatment. Methods: 84 ACS patients who underwent PCI in our hospital from December 1, 2018 to December 1, 2019 were selected and divided into control group (n = 42) and study group (n = 42) according to the random number table. The control group was treated with statins, and the study group was treated with alloxan combined therapy. The changes of blood lipid index, quality of life score, adverse cardiovascular and cerebrovascular events and adverse reactions were compared before and after treatment. Results: There was no significant difference in TCHO, TG, HDL-C and LDL-C between the two groups before treatment (P>0.05);After treatment, the levels of TCHO, TG, HDL-C and LDL-C in the study group were significantly lower than those in the control group (P<0.05);There was no significant difference in the scores of WHOQOL-BREF before treatment (P>0.05);After treatment, the WHOQOL-BREF scores of the two groups were improved, and the study group was significantly higher than the control group (P<0.05);The incidence of adverse cardiovascular and cerebrovascular events and adverse reactions in the study group was lower than that in the control group, but the difference was not statistically significant (P>0.05). Conclusion: After percutaneous coronary intervention in patients with acute coronary syndrome, the use of Elojumab can effectively reduce the blood lipid index, improve the quality of patients and reduce the incidence of adverse cardiovascular and cerebrovascular events and adverse reactions, which can be effectively promoted in clinical practice.